Abstract
Background: The transduction of cancer cells using recombinant adeno-associated virus (rAAV) occurs with low efficiency, which limits its utility in cancer gene therapy. We have previously sought to enhance rAAV-mediated transduction of cancer cells by applying DNA-damaging stresses. An alternative technique to improve the rAAV-mediated transduction of tumor cells is enhancement at a transcription step. Treatment with a histone deacetylase (HDAC) inhibitor is known to recover the gene expression from a silenced rAAV genome that has been integrated into the host's genome. However, rAAV exists mostly as an extrachromosomal genome rather than as an integrated genome, and this extrachromosomal form is the primary source of gene expression. We examined whether the HDAC inhibitor could contribute to the enhanced transcription before integration occurs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
